Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.

Ganguly S, Panetta JC, Roberts JK, Schuetz EG.

Drug Metab Dispos. 2018 Jul;46(7):1014-1022. doi: 10.1124/dmd.117.078360. Epub 2018 Apr 19.

PMID:
29674491
2.

Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.

Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B.

Drug Metab Dispos. 2018 Jun;46(6):888-896. doi: 10.1124/dmd.118.080952. Epub 2018 Mar 30.

PMID:
29602798
3.

Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Crawford RR, Potukuchi PK, Schuetz EG, Schuetz JD.

Drug Metab Dispos. 2018 May;46(5):567-580. doi: 10.1124/dmd.118.080663. Epub 2018 Mar 7.

PMID:
29514827
4.

Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans.

Wong T, Wang Z, Chapron BD, Suzuki M, Claw KG, Gao C, Foti RS, Prasad B, Chapron A, Calamia J, Chaudhry A, Schuetz EG, Horst RL, Mao Q, de Boer IH, Thornton TA, Thummel KE.

Drug Metab Dispos. 2018 Apr;46(4):367-379. doi: 10.1124/dmd.117.078428. Epub 2018 Jan 17.

PMID:
29343609
5.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF.

Pharmacogenet Genomics. 2018 Jan;28(1):7-16. doi: 10.1097/FPC.0000000000000317.

PMID:
29232328
6.

Zebrafish abcb11b mutant reveals strategies to restore bile excretion impaired by bile salt export pump deficiency.

Ellis JL, Bove KE, Schuetz EG, Leino D, Valencia CA, Schuetz JD, Miethke A, Yin C.

Hepatology. 2018 Apr;67(4):1531-1545. doi: 10.1002/hep.29632. Epub 2018 Feb 23.

PMID:
29091294
7.

CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.

Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, Jacobson PA, Israni AK.

Drug Metab Dispos. 2017 Aug;45(8):957-965. doi: 10.1124/dmd.117.076307. Epub 2017 May 22.

8.

Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.

Tanner JA, Prasad B, Claw KG, Stapleton P, Chaudhry A, Schuetz EG, Thummel KE, Tyndale RF.

J Pharmacol Exp Ther. 2017 Jan;360(1):129-139. Epub 2016 Nov 4.

9.

Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.

Thomson MM, Hines RN, Schuetz EG, Meibohm B.

Drug Metab Dispos. 2016 Jul;44(7):999-1004. doi: 10.1124/dmd.115.069252. Epub 2016 Apr 20.

10.

Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.

Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz DL, Sadee W, Nickerson DA, Krauss RM, George AL, Schuetz EG, Medina MW, Cox NJ, Scherer SE, Giacomini KM, Brenner SE.

Pharmacogenomics J. 2017 Mar;17(2):137-145. doi: 10.1038/tpj.2015.93. Epub 2016 Feb 9.

11.

Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, Shireman LM, Tay-Sontheimer J, Lin YS.

Drug Metab Dispos. 2016 Mar;44(3):343-51. doi: 10.1124/dmd.115.067900. Epub 2015 Dec 17. Review.

12.

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE.

Pharmacogenomics J. 2016 Aug;16(4):375-87. doi: 10.1038/tpj.2015.58. Epub 2015 Sep 1.

13.

In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice.

Yasuda K, Cline C, Lin YS, Scheib R, Ganguly S, Thirumaran RK, Chaudhry A, Kim RB, Schuetz EG.

Drug Metab Dispos. 2015 Nov;43(11):1646-54. doi: 10.1124/dmd.115.065078. Epub 2015 Aug 17.

14.

Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo.

Wang YM, Chai SC, Lin W, Chai X, Elias A, Wu J, Ong SS, Pondugula SR, Beard JA, Schuetz EG, Zeng S, Xie W, Chen T.

Biochem Pharmacol. 2015 Aug 15;96(4):357-68. doi: 10.1016/j.bcp.2015.06.018. Epub 2015 Jun 25.

15.

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, Schuetz EG.

Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28.

16.

Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability.

Wang Z, Wong T, Hashizume T, Dickmann LZ, Scian M, Koszewski NJ, Goff JP, Horst RL, Chaudhry AS, Schuetz EG, Thummel KE.

Endocrinology. 2014 Jun;155(6):2052-63. doi: 10.1210/en.2013-2013. Epub 2014 Mar 18.

17.

Why do most human liver cytosol preparations lack xanthine oxidase activity?

Barr JT, Choughule KV, Nepal S, Wong T, Chaudhry AS, Joswig-Jones CA, Zientek M, Strom SC, Schuetz EG, Thummel KE, Jones JP.

Drug Metab Dispos. 2014 Apr;42(4):695-9. doi: 10.1124/dmd.113.056374. Epub 2014 Jan 15.

18.

Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1.

Wang YM, Lin W, Chai SC, Wu J, Ong SS, Schuetz EG, Chen T.

Toxicol Appl Pharmacol. 2013 Oct 1;272(1):96-107. doi: 10.1016/j.taap.2013.05.014. Epub 2013 May 22.

19.

Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s.

Chaudhry AS, Thirumaran RK, Yasuda K, Yang X, Fan Y, Strom SC, Schuetz EG.

Drug Metab Dispos. 2013 Aug;41(8):1538-47. doi: 10.1124/dmd.113.051672. Epub 2013 May 23. Erratum in: Drug Metab Dispos. 2014 May;42(5):917.

20.

Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.

Yasuda K, Cline C, Vogel P, Onciu M, Fatima S, Sorrentino BP, Thirumaran RK, Ekins S, Urade Y, Fujimori K, Schuetz EG.

Drug Metab Dispos. 2013 Apr;41(4):923-31. doi: 10.1124/dmd.112.050344. Epub 2013 Jan 8.

21.

The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD, Stewart PW, Lindley CM, Chen ML.

Drug Metab Dispos. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13.

22.

Interplay between vitamin D and the drug metabolizing enzyme CYP3A4.

Wang Z, Schuetz EG, Xu Y, Thummel KE.

J Steroid Biochem Mol Biol. 2013 Jul;136:54-8. doi: 10.1016/j.jsbmb.2012.09.012. Epub 2012 Sep 15. Review.

23.

Ontogeny and sorafenib metabolism.

Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD.

Clin Cancer Res. 2012 Oct 15;18(20):5788-95. doi: 10.1158/1078-0432.CCR-12-1967. Epub 2012 Aug 27.

24.

Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells.

Zheng XE, Wang Z, Liao MZ, Lin YS, Shuhart MC, Schuetz EG, Thummel KE.

Biochem Pharmacol. 2012 Aug 1;84(3):391-401. doi: 10.1016/j.bcp.2012.04.019. Epub 2012 May 4.

25.

Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.

Kalabus JL, Cheng Q, Jamil RG, Schuetz EG, Blanco JG.

Toxicol Lett. 2012 Jun 20;211(3):266-73. doi: 10.1016/j.toxlet.2012.04.006. Epub 2012 Apr 15.

26.

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, Hall SD, Schuetz EG.

Biochem Pharmacol. 2012 Jul 1;84(1):104-12. doi: 10.1016/j.bcp.2012.03.017. Epub 2012 Mar 30.

27.

PharmGKB summary: very important pharmacogene information for CYP3A5.

Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB.

Pharmacogenet Genomics. 2012 Jul;22(7):555-8. doi: 10.1097/FPC.0b013e328351d47f. No abstract available.

28.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, Kashuba AD, Corbett AH.

Pharmacogenomics. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

29.

Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction.

Wang Y, Guan S, Acharya P, Liu Y, Thirumaran RK, Brandman R, Schuetz EG, Burlingame AL, Correia MA.

Mol Cell Proteomics. 2012 Feb;11(2):M111.010132. doi: 10.1074/mcp.M111.010132. Epub 2011 Nov 17.

30.

Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis.

Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry AS, Mansell S, Leon-Ponte M, Strom SC, Zaher H, Schwarz UI, Freeman DJ, Schuetz EG, Tirona RG, Kim RB.

Hepatology. 2011 Aug;54(2):644-54. doi: 10.1002/hep.24391. Epub 2011 Jun 26.

31.

Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.

Smith NF, Mani S, Schuetz EG, Yasuda K, Sissung TM, Bates SE, Figg WD, Sparreboom A.

Ann Pharmacother. 2010 Nov;44(11):1709-17. doi: 10.1345/aph.1P354. Epub 2010 Oct 19.

32.

Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1.

Meyer Zu Schwabedissen HE, Böttcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB.

Hepatology. 2010 Nov;52(5):1797-807. doi: 10.1002/hep.23876.

PMID:
20827719
33.

Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Lamba V, Panetta JC, Strom S, Schuetz EG.

J Pharmacol Exp Ther. 2010 Mar;332(3):1088-99. doi: 10.1124/jpet.109.160804. Epub 2009 Nov 24.

34.

CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG.

J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.

35.

Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE.

Mol Pharmacol. 2009 Nov;76(5):946-56. doi: 10.1124/mol.109.056192. Epub 2009 Jul 24.

36.

Etoposide pathway.

Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB.

Pharmacogenet Genomics. 2009 Jul;19(7):552-3. doi: 10.1097/FPC.0b013e32832e0e7f. No abstract available.

37.

The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation.

Lin YS, Yasuda K, Assem M, Cline C, Barber J, Li CW, Kholodovych V, Ai N, Chen JD, Welsh WJ, Ekins S, Schuetz EG.

Drug Metab Dispos. 2009 Jun;37(6):1295-304. doi: 10.1124/dmd.108.025213. Epub 2009 Feb 27.

38.

A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor.

Pondugula SR, Brimer-Cline C, Wu J, Schuetz EG, Tyagi RK, Chen T.

Drug Metab Dispos. 2009 Apr;37(4):719-30. doi: 10.1124/dmd.108.024695. Epub 2009 Jan 26.

39.

Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A.

Pharmacogenomics J. 2009 Feb;9(1):49-60. doi: 10.1038/tpj.2008.13. Epub 2008 Sep 30.

40.

Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.

Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A.

Clin Pharmacol Ther. 2008 Dec;84(6):704-9. doi: 10.1038/clpt.2008.94. Epub 2008 May 28. Review.

PMID:
18509328
41.

Pharmacogenetic pathway analysis of docetaxel elimination.

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A.

Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28.

42.

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL.

Drug Metab Dispos. 2008 Aug;36(8):1465-9. doi: 10.1124/dmd.107.020065. Epub 2008 May 19.

43.

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.

Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.

Drug Metab Dispos. 2008 Jan;36(1):146-54. Epub 2007 Oct 22.

44.

Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.

Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R.

J Pharmacol Exp Ther. 2007 Dec;323(3):935-45. Epub 2007 Sep 12.

45.
46.

A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.

Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB.

Mol Endocrinol. 2007 Aug;21(8):1769-80. Epub 2007 May 22.

PMID:
17519356
47.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.

Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):488-96. Epub 2006 Jul 20.

48.

Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.

Lamba JK, Chen X, Lan LB, Kim JW, Wei Wang X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG.

Pharmacogenet Genomics. 2006 Jun;16(6):415-27.

PMID:
16708050
49.

Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.

Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE.

J Clin Invest. 2006 Jun;116(6):1703-12. Epub 2006 May 11.

50.

Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.

Ramírez J, Komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, Innocenti F, Strom SC.

Pharmacogenet Genomics. 2006 Feb;16(2):79-86.

PMID:
16424820

Supplemental Content

Loading ...
Support Center